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a b s t r a c t
Objective: Make an analysis of the factors that influence their survival and prognosis of 
patients with osteosarcoma treated at a Charity Hospital in Teresina-PI. Methods: We 
analyzed medical records of 32 patients diagnosed with osteosarcoma in the period January 
2005 to December 2010. Results: Patients were aged between 6 and 73 years, with 56.2% 
men and 43.7% women. The prevailing color was black, with 62.5% of cases. With regard to 
histological subtype, the majority were osteoblastic type (71.8%). The anatomical location 
of the tumor was prevalent region of the knee (distal femur and proximal tibia). Regarding 
the size of the tumor, tumors were 43.8% bigger than 15 cm. Degree of necrosis Huvos 
concentrated primarily among the types I and II, 53.1% and 25% respectively. The overall 
survival at two and four years was 45.5% and 39% respectively and event- free survival at 
two and four years was 39.8% and 19.9% respectively. Conclusion: We considered the worst 
prognosis, the presence of metastases at diagnosis and tumors larger than 15 cm. And the 
criteria of Huvos did not reach statistical significance for the prognosis of patients.
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absence of metastasis over the course of the study, location 
of the metastasis and data of appearance, tumor staging at 
the time of diagnosis, presence or absence of local recurrence 
after the surgical treatment, and date of the patient’s death, if 
this occurred during the period of the study.
The patients of the present study were treated based 
on the Brazilian protocols for chemotherapy treatment 
for osteosarcomas (both metastatic and non-metastatic). 
The statistical analyses were performed using the SPSS 
statistical software (version 9.0). Initially, the simple 
frequencies of all the variables studied were calculated. 
Subsequently, the accumulated survival probabilities were 
calculated by means of the Kaplan-Meier technique. All 
the variables were analyzed regarding their importance 
in relation to the prognosis, for event-free survival 
(percentage of patients who up to a given date, remained 
free from local and/or systemic manifestations) and 
for overall survival (percentage of patients who were 
still alive up to a given date). The Huvos grade (I, II, III or 
IV), tumor size (< 15 or > 15 cm), presence of metastasis at 
diagnosis and surgical treatment used (radical or salvage) were 
evaluated as variables to determine their prognostic value, in 
relation to survival, using the log-rank test.
Results
The patients’ ages ranged from 6 to 73 years, with a median of 
15 years; 56.2% were aged less than or equal to 15 years and 
43.7% were over 15 years of age. In relation to sex, 56.2% were 
men and 43.7% were women. The most prevalent color was 
black, accounting for 62.5% of the cases, followed by mixed 
(21.8%) and white (15.6%). Regarding the variable of occupation, 
90.6% of the patients were students. 
In relation to histological subtype, 71.8% were osteoblastic, 
21.8% were chondroblastic and 6.2% were rich in giant cells.
The anatomical location of the tumor had the following 
distribution: 50% distal femur, 21.8% proximal tibia, 
9.4% proximal femur and 9.4% proximal humerus. The distal 
tibia, proximal fibula and distal fibula presented one case each 
(percentage of 3.1%).
The tumor sizes were divided into less than or equal to 15 cm 
(56.2%) and greater than 15 cm (43.8%). In relation to the Huvos 
necrosis grade, 17 patients (53.1%) presented Huvos I, 8 (25%) 
had Huvos II, 7 (21.8%) had Huvos III and none had Huvos IV.
Regarding metastasis, 20 patients (62.5%) developed this 
at some time over the course of the disease. Of these, seven 
(21.8%) already had a metastasis at the time of the diagnosis. 
Introduction
Neoplasia occupies second place among Brazilian mortality 
rates, only behind circulatory diseases, which therefore makes 
cancer a public health problem.1
Among all forms of neoplasia in general, primary bone 
tumors constitute 3% to 4%. Furthermore, in the Brazilian 
setting, the definitive diagnoses for cases of primary bone 
tumors tend to be delayed. Early diagnosis for these forms 
of neoplasia is fundamentally important, especially in 
relation to malignant tumors, for which local control and 
therapeutic management aimed at increasing these patients’ 
survival are needed.1 
Osteosarcoma is the commonest type of bone tumor 
with a primary malignant bone matrix, accounting for 0.2% 
of human malignant neoplasia. It was first described by 
Dupuytren in 1805, and its main characteristic consists of 
production of osteoid matrix by neoplastic cells. It mainly affects 
children and adolescents during their first two decades of life 
and its favored anatomical position is the metaphyses of long 
bones. The distal femur and proximal tibia are the locations 
most frequently affected by osteosarcoma, followed by the 
proximal humerus.1
Today, it can be said that the prognosis for patients with 
osteosarcoma depends on the size of the tumor, the surgical 
margins achieved during the operation and any presence of 
pulmonary metastases.2
It is also known that factors such as sex and anatomical 
location of the lesion are not associated with local recurrence 
or with the prognosis, while the percentage induction of 
necrosis by chemotherapy and the surgical margins are factors 
associated with local control.2
This study had the aims of analyzing the factors that 
were influencing prognosis and survival among patients 
attended at a philanthropic hospital in Teresina, Piauí, and 
epidemiologically and clinically characterizing the sample. 
Each factor was evaluated separately and together, with the 
aim of finding a better diagnostic and therapeutic approach 
for the patients affected by this disease. 
Sample and methods
After gaining approval from the Research Ethics Committee of 
UFPI, with CAAE registration no. 0399.0.045.000-11, and approval 
from the National Research Ethics Commission (CONEP), 
with registration number 045, a descriptive-analytical 
quantitative retrospective cross-sectional study was begun, 
covering the period from January 2005 to December 2010. The 
medical files of 32 patients who had been diagnosed with 
osteosarcoma at a philanthropic hospital in Teresina, Piauí, 
were analyzed.
In evaluating the medical files, the following data were 
gathered: age, sex, color, occupation, date of diagnosis of 
osteosarcoma, Huvos criterion (Table 1), size and anatomical 
location of the tumor, histological subtype, presence of lymph 
fluid and/or blood invasion, surgical treatment used, surgical 
limits found from histopathological evaluation, presence or 
Types Huvos criteria
Grade I No effect from chemotherapy
Grade II Partial response with necrosis of more than 50%
Grade III Necrosis of more than 90%, with viable tumor present
Grade IV No viable tumor
Table 1 - Incidence of complaints per category.
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Among the metastasis sites were the following: lung (100%), 
bone (25%), liver (5%) and others (15%).
In relation to the surgical treatment, 65.6% of the patients 
underwent radical surgery (amputation), while 34.4% were 
able to benefit from salvage surgery on the limb. Among the 
patients with larger-sized tumors (> 15 cm), 85.7% underwent 
radical surgery.
Two cases of local recurrence were observed (6.2%) and 
62.5% of the patients died due to osteosarcoma.
The overall survival curve is shown in Fig. 1 and the two and 
four-year rates were 45.5% and 39%, respectively. The event-free 
survival curve is shown in Fig. 2 and the two and four-year rates 
were 39.8% and 19.9%, respectively. 
The factor that significantly influenced overall survival in the 
univariate analysis was the surgical treatment (p = 0.0002), as 
illustrated in Fig. 3. Radical surgical treatment was considered 
to be an adverse factor, in comparison with salvage treatment, 
since it presented a higher mortality rate. Other factors such 
as sex, age, tumor location, histological subtype, tumor size, 
metastasis at the time of diagnosis and surgical limits, did not 
reach statistically significant limits, for p-values < 0.05.
The factors that had an influence on the risk of an event 
(metastasis and/or local recurrence) in the univariate analysis 
were the following: surgical treatment (p = 0.0037; Fig. 4), 
metastasis at the time of diagnosis (p = 0.0016; Fig. 5) and tumor 
size (p = 0.0502; Fig. 6). Radical surgical treatment was considered 
to be an adverse factor for events to appear (metastasis and/
or local recurrence), in comparison with salvage treatment. 
Presence of metastasis at the time of diagnosis showed a 
greater rate of events (metastasis and/or local recurrence), 
in comparison with its absence, and tumor size greater than 
15 cm along its major axis was considered to be an adverse 
factor for event-free survival. The other factors studied did not 
present significance levels for p-values < 0.05 (sex, age, tumor 
location, histological subtype and surgical limits).
The degrees of tumor necrosis following chemotherapy 
(Huvos) did not reach statistical significance levels for the 
two survival types: overall (p = 0.2903) and event-free (0.5327), 
as shown in Figs. 7 and 8. Huvos grades were not considered to 
be prognostic factors for either overall or event-free survival.
Fig. 1 - Overall survival curve.
Fig. 2 - Event-free survival curve.
Fig. 3 - Overall survival curve according to surgical treatment.
Fig. 4 - Event-free survival curve according to surgical 
treatment.
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Fig. 5 - Event-free survival curve according to metastasis at 
the time of diagnosis.
Fig. 6 - Event-free survival curve according to tumor size
Fig. 7 - Overall survival curve according to Huvos necrosis 
grade.
Fig. 8 - Event-free survival curve according to Huvos 
necrosis grade.
Discussion
The epidemiological and clinical characterization in the 
present study was concordant with the literature.1-3 
The unfavorable prognostic factors were metastasis 
at the time of diagnosis, tumor size larger than 15 cm and 
radical surgical treatment. During the follow-up among these 
patients, metastases were identified in 62.5% of them, among 
whom 21.8% had already presented metastasis at the time of 
diagnosis. This percentage was, in turn, higher than values 
reported from other countries (15% to 20%), but it was within 
the range reported in Brazil, which has been as high as 38%.4 
In evaluating its significance for event-free survival, we found 
that it was related to worse prognosis. Rech et al.5 also came 
to this conclusion, through demonstrating that less than 20% 
of these patients present five-year disease-free survival.5 
These patients probably demonstrated worse survival results 
because they had larger-sized tumors during the initial stages 
of the disease and because these cases were diagnosed at a 
late stage.4,5 
In our study, 43.8% of the patients presented tumor sizes 
larger than 15 cm, and these patients had worse event-free 
survival results. This corroborates the data of Bispo Júnior,6 in 
a doctoral thesis, and the findings of Castro et al.4
The patients’ overall survival after two and four years was 
45.5% and 39%, respectively. Other studies4,6 have reported 
overall survival rates higher than those found in our study. 
In evaluating event-free survival, we observed two and 
four-year rates of 39.8% and 19.9%, respectively. Similar studies 
have revealed higher rates.4-6 
The type of surgical treatment (amputation or limb 
preservation) was chosen for the patients in accordance 
with the concomitant conditions presented. In other words, 
the decision was made according to the degree to which the 
disease had already evolved. Patients whose diagnoses were 
made at a late stage, with metastatic disease and/or large-
volume tumors, almost always underwent radical surgery. In 
this manner, 65.6% of the patients underwent amputation. 
Although the patients with an indication for salvage surgery 
on the limb had a greater chance of presenting local recurrence, 
depending on the surgical technique and the learning 
curve, they presented overall and event-free survival rates 
greater than those of patients who underwent amputation.7,8 
This was because the patients with voluminous tumors 
(with the implication of impossibility of limb preservation) 
presented worse prognosis even at the time of diagnosis.8,9 
We evaluated the Huvos criteria but found that they did 
not present any significance in relation to the patients’ 
prognoses. In a doctoral thesis, Bispo Júnior6 reported that the 
stratification into groups I and II was unnecessary because 
of the similar behavior presented by these two groups, and 
also demonstrated that the prognostic behavior was similar 
between the groups.
Other criteria for prognostic evaluation and staging have 
already been proposed in the worldwide literature.10,11 
Magnetic resonance imaging may in the future be used for 
assessing the degree of tumor necrosis following neoadjuvant 
chemotherapy. 
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Conclusion
According to this study, presence of metastasis at the time of 
diagnosis and tumor size larger than 15 cm were factors for 
worse prognosis. On the other hand, the Huvos criteria did 
not reach statistical significance for the patients’ prognoses. 
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